{"id":4647,"date":"2022-02-07T11:35:20","date_gmt":"2022-02-07T17:35:20","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=4647"},"modified":"2025-07-25T11:13:50","modified_gmt":"2025-07-25T16:13:50","slug":"nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/","title":{"rendered":"Nanoscope Therapeutics anuncia la inscripci\u00f3n completa de su ensayo cl\u00ednico de fase 2b en pacientes ciegos para la terapia g\u00e9nica optogen\u00e9tica para restaurar la visi\u00f3n"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"4647\" class=\"elementor elementor-4647\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-707c2e9c elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"707c2e9c\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-449ec8fc\" data-id=\"449ec8fc\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3c1d9f1f elementor-widget elementor-widget-text-editor\" data-id=\"3c1d9f1f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>DALLAS, <span class=\"xn-chron\">7 de febrero de 2022<\/span>\u00a0 \u2014\u00a0<a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Terap\u00e9utica del nanoscopio<\/a>, una empresa de biotecnolog\u00eda en etapa cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy la inscripci\u00f3n completa de su fase <span class=\"xn-money\">2b<\/span> Ensayo cl\u00ednico de MCO-010, una monoterapia optogen\u00e9tica con opsina multicaracter\u00edstica (MCO) activable con luz ambiental para restaurar la visi\u00f3n en pacientes con retinitis pigmentosa (RP). Se esperan resultados de primera l\u00ednea en el primer trimestre del pr\u00f3ximo a\u00f1o.<\/p><p>\u201cCompletar la inscripci\u00f3n para este ensayo es otro hito importante para Nanoscope y para millones de personas que sufren enfermedades de la retina para las que no existen tratamientos eficaces\u201d, dijo. <span class=\"xn-person\">Sulagna Bhattacharya<\/span>, director ejecutivo de Nanoscope. \u201cLos resultados positivos de este ensayo nos acercar\u00e1n a satisfacer esta importante necesidad m\u00e9dica no cubierta\u201d.\u201d<\/p><p><a href=\"https:\/\/nanostherapeutics.com\/es\/2021\/06\/03\/nanoscopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision\/\" target=\"_blank\" rel=\"nofollow noopener\">Un estudio de fase 1\/2a completado de MCO-010<\/a>\u00a0en 11 pacientes con RP demostraron que la terapia optogen\u00e9tica fue bien tolerada, con una mejor calidad de vida consistente con una mejora funcional significativa de la visi\u00f3n en pacientes con RP avanzada.<\/p><p>La fase <span class=\"xn-money\">2b<\/span> ensayo (<u><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a><\/u>) inscribieron a 27 participantes con p\u00e9rdida grave de visi\u00f3n debido a RP avanzada en un ensayo multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada. En este estudio, los pacientes reciben una inyecci\u00f3n de MCO-010 o una inyecci\u00f3n simulada para evaluar la eficacia y seguridad de la terapia con MCO-010.<\/p><p>\u201cLa retinosis pigmentaria es una enfermedad hereditaria progresiva causada por un espectro de diferentes mutaciones gen\u00e9ticas. Esta terapia optogen\u00e9tica tiene el potencial de impactar a pacientes con diversos tipos gen\u00e9ticos de retinosis pigmentaria\u201d, dijo. <span class=\"xn-person\">Byron Lam<\/span>, MD, profesor de neurooftalmolog\u00eda en Bascom Palmer Eye Institute y destacado experto en RP.<\/p><p>La terapia optogen\u00e9tica de Nanoscope utiliza un sistema patentado. <i>AAV2<\/i> vector para introducir genes MCO en las c\u00e9lulas de la retina, permitiendo la visi\u00f3n en entornos naturales. La terapia se administra como una \u00fanica inyecci\u00f3n en el ojo para administraci\u00f3n en el consultorio sin necesidad de ning\u00fan otro dispositivo o intervenci\u00f3n. Seg\u00fan la evidencia del estudio de Fase 1\/2a, MCO-010 es potencialmente aplicable para la restauraci\u00f3n de la visi\u00f3n en enfermedades degenerativas de la retina, independientemente de las mutaciones gen\u00e9ticas. MCO-010 ha recibido designaciones de medicamento hu\u00e9rfano para la RP y la enfermedad de Stargardt por parte de la FDA. Tambi\u00e9n se est\u00e1 iniciando un estudio de fase 2 sobre la degeneraci\u00f3n macular de Stargardt.<\/p><p><b>Acerca de RP\u00a0<br class=\"dnr\" \/><\/b>La RP, vinculada a m\u00e1s de 100 mutaciones gen\u00e9ticas diferentes, abarca un grupo de trastornos raros en los que los fotorreceptores se degradan, lo que provoca ceguera en aproximadamente 2 millones de personas.<\/p><p><b>Acerca de la terap\u00e9utica con nanoscopios<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas para restaurar la vista en millones de personas ciegas que padecen enfermedades de la retina, para las que no existe cura. La cartera incluye terapias optogen\u00e9ticas para RP, Stargardt y DMAE seca.<\/p><p><b>Contacto:<br class=\"dnr\" \/><\/b><span class=\"xn-person\">Dan Eramian<\/span><br class=\"dnr\" \/>Comunicaciones Opus Biotech<br class=\"dnr\" \/><a href=\"mailto:pr@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">pr@nanostherapeutics.com<\/a><br class=\"dnr\" \/>425-306-8716<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>DALLAS, Feb. 7, 2022\u00a0 \u2014\u00a0Nanoscope Therapeutics, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2b clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in patients with retinitis pigmentosa (RP). Topline results are expected in Q1 of next year. [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":4650,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-4647","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-07T17:35:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-25T16:13:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision\",\"datePublished\":\"2022-02-07T17:35:20+00:00\",\"dateModified\":\"2025-07-25T16:13:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/\"},\"wordCount\":405,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/NSCOPE_LI_fullenrollment.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/\",\"name\":\"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/NSCOPE_LI_fullenrollment.jpg\",\"datePublished\":\"2022-02-07T17:35:20+00:00\",\"dateModified\":\"2025-07-25T16:13:50+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/NSCOPE_LI_fullenrollment.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/NSCOPE_LI_fullenrollment.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia la finalizaci\u00f3n del reclutamiento de pacientes para su ensayo cl\u00ednico de fase 2b en pacientes ciegos para la terapia g\u00e9nica optogen\u00e9tica con el fin de restaurar la visi\u00f3n - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2022-02-07T17:35:20+00:00","article_modified_time":"2025-07-25T16:13:50+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision","datePublished":"2022-02-07T17:35:20+00:00","dateModified":"2025-07-25T16:13:50+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/"},"wordCount":405,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/","url":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/","name":"Nanoscope Therapeutics anuncia la finalizaci\u00f3n del reclutamiento de pacientes para su ensayo cl\u00ednico de fase 2b en pacientes ciegos para la terapia g\u00e9nica optogen\u00e9tica con el fin de restaurar la visi\u00f3n - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg","datePublished":"2022-02-07T17:35:20+00:00","dateModified":"2025-07-25T16:13:50+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/4647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=4647"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/4647\/revisions"}],"predecessor-version":[{"id":9240,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/4647\/revisions\/9240"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/4650"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=4647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=4647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=4647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}